Effects of serum containing Wuzang Wenyang Huayu Decoction on phosphorylated-tau protein expression in Alzheimer’s disease cell model

doi:10.12307/2022.146

Abstract

Abstract: BACKGROUND: Various previous studies have shown that Wuzang Wenyang Huayu Decoction has a good therapeutic effect on Alzheimer’s disease, but its pharmacological mechanism has not been fully elucidated.
OBJECTIVE: To investigate the effect of Wuzang Wenyang Huayu Decoction drug-containing serum on the expression of peroxisome proliferator-activated receptor γ and phosphorylated-tau protein in Alzheimer’s disease cell model.
METHODS: Beta amyloid protein was used to induce primary hippocampal neurons to establish the currently recognized Alzheimer’s disease cell model. Wuzang Wenyang Huayu Decoction drug-containing serum and donepezil hydrochloride drug-containing serum were given for intervention for 72 hours. The dendritic length and branch number of primary neurons cells were detected by immunofluorescence assay. The expression levels of peroxisome proliferator-activated receptor γ and phosphorylated-tau protein were detected by western blot assay.
RESULTS AND CONCLUSION: Compared with the control group, the length and branch number of dendritic cells in the model group were significantly decreased (P < 0.05), peroxisome proliferator-activated receptor γ expression decreased, and phosphorylated-tau protein increased (P < 0. 05 or P < 0. 01). Compared with the model group, the dendritic length and branch number of neurons in Wuzang Wenyang Huayu group and donepezil hydrochloride group increased, the expression of PPARγ increased, and the expression of phosphorylated-tau protein significantly decreased (P < 0. 05 or P < 0. 01). Results confirmed that Wuzang Wenyang Huayu Decoction has neuroprotective effect on Alzheimer’s disease cells induced by beta amyloid protein, and its mechanism may be related to upregulation of peroxisome proliferator-activated receptor γ protein and inhibition of phosphorylated-tau protein.

Key words: neuron, Alzheimer’s disease, Wuzang Wenyang Huayu Decoction, beta amyloid protein, peroxisome proliferator-activated receptor γ, phosphorylated-tau protein

CLC Number:

Wen Xiaoyu, Sun Yuhao, Xia Meng. Effects of serum containing Wuzang Wenyang Huayu Decoction on phosphorylated-tau protein expression in Alzheimer’s disease cell model[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(7): 1068-1073.

Figures/Tables 4

References

[1] 卢冲,李新宇,孙宇,等.胰高血糖素样肽1(GLP-1)改善阿尔茨海默病大鼠模型的认知功能及其机制研究[J].卒中与神经疾病,2019, 26(2):193-197.
[2] HARDY J, SELKOE DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-356.
[3] 唐睿.阿尔茨海默病发病机理与治疗策略[J].中山大学研究生学刊(自然科学、医学版),2013,34(2):31-42.
[4] DU J, ZHANG L, LIU S, et al. PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons. Biochem Biophys Res Commun. 2009;383(4):485-490.
[5] 邓燕.五脏温阳化瘀汤治疗老年性痴呆的疗效研究[D].南宁:广西中医药大学,2017.
[6] 王韵桥,夏猛,曹传东,等.五脏温阳化瘀汤对血管性痴呆模型大鼠海马组织PI3K/Akt-mTOR信号通路的影响[J].中医杂志,2019, 60(16):1412-1416.
[7] 王韵桥,夏猛,唐农.五脏温阳化瘀法治疗老年期痴呆[J].中医学报,2019,34(10):2075-2078.
[8] 陈炜,吴林,胡跃强,等.五脏温阳化瘀汤治疗肾虚血瘀型老年性痴呆30例临床研究[J].湖南中医杂志,2018,34(9):4-6,15.
[9] 梁晓兵.五脏温阳化瘀汤治疗动脉硬化性血管性老年痴呆疗效观察[J].内蒙古中医药,2019,38(2):6-7.
[10] 唐农,王晋平,吴林,等.五脏温阳化瘀胶囊治疗血管性痴呆临床疗效观察[J].辽宁中医药大学学报,2015,17(9):25-27.
[11] 翟阳,唐农,黎军宏,等.五脏温阳化瘀胶囊治疗血管性痴呆的随机对照临床研究[J].辽宁中医杂志,2017,44(6):1212-1214.
[12] 向军军.五脏温阳化瘀汤治疗阳虚型血管性痴呆的临床疗效观察[D].南宁:广西中医药大学,2016.
[13] 农微,卫智权,莫雪妮,等.五脏温阳化瘀汤抑制周期蛋白依赖激酶-5过表达对SAMP8小鼠脑神经纤维缠结的影响[J].中国实验方剂学杂志,2019,25(9):61-66.
[14] 王韵桥,夏猛,曹传东,等.五脏温阳化瘀汤对血管性痴呆模型大鼠Bcl-2及Caspase相关蛋白表达的影响[J].中华中医药杂志,2020, 35(2):625-628.
[15] 李仪奎.中药血清药理学实验方法的若干问题[J].中药新药与临床药理,1999(2):95.
[16] 张灵娜,林兵,宋洪涛.中药血清药理学、血清药物化学的研究概况及展望[J].中草药,2015,46(17):2662-2666.
[17] 郑衍芳,孙田静,郑丽萍,等.Aβ(1-42)寡聚体诱导阿尔茨海默病动物模型的研究[J].医学综述,2016,22(15):2954-2956.
[18] 张龙. Aβ1-42寡聚体2对PC-12胰岛素P13K/PKB信号转导通路的影响[D].遵义:遵义医学院,2013.
[19] 张婉涛,刘玲,董欢欢.五脏生理病理特点在血管性认知障碍发病中的作用[J].湖北中医药大学学报,2014,16(1):70-71.
[20] 唐农, 古联,严雁.五脏温阳化瘀汤治疗动脉硬化性血管性痴呆87例临床疗效观察[J].时珍国医国药,2015,26 (6) :1421-1422.
[21] 张海燕,唐农,葛金文,等.五脏温阳化瘀汤对动脉粥样硬化血管性痴呆大鼠海马组织 Nrf2 蛋白通路的影响[J].云南中医学院学报, 2013,36(3):8-11.
[22] 张海燕.五脏温阳化瘀汤对动脉粥样硬化血管性痴呆大鼠作用机理的研究[D].长沙:湖南中医药大学,2013.
[23] 周利.阿尔兹海默症发病过程Aβ降解酶的变化规律和相互关系以及初步药物研究[D].上海:华东理工大学,2016.
[24] 卫智权,农微,莫雪妮,等.五脏温阳化瘀汤对SAMP8小鼠Tau蛋白过磷酸化与神经纤维缠结的抑制作用[J].中华中医药学刊, 2019,37(11):2583-2587,2818-2819.
[25] 农微,卫智权,莫雪妮,等.五脏温阳化瘀汤调节蛋白磷酸酶2A甲基化对Tau蛋白过磷酸化的抑制作用[J].时珍国医国药,2019, 30(8):1810-1813.
[26] 王金春,刘慧影,曹云鹏.tau蛋白与阿尔茨海默病[J].中国组织工程研究,2020,24(17):2775-2781.
[27] 莫玉言,侯加卫,周张玖智,等.星形胶质细胞调控下红花黄色素对Aβ(1-42)介导的海马神经元突触损伤的保护作用研究[J].石河子大学学报(自然科学版),2019,37(1):47-54.
[28] RAPOPORT M, DAWSON HN, BINDER LI, et al. Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99(9): 6364-6369.
[29] 王丹琼,卜星彭,王蕾,等.替米沙坦对高血压合并阿尔茨海默病患者血清Aβ蛋白、Tau蛋白和炎性细胞因子的影响[J].山西医科大学学报,2017,48(6):546-549.
[30] CAMACHO IE, SERNEELS L, SPITTAELS K, et al. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci. 2004;24(48):10908-10917.
[31] GURLEY C, NICHOLS J, LIU S, et al. Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-gamma Agonists. PPAR Res. 2008;2008:453120.
[32] 晏昆,蒙凌,陈玉芳.PPARγ基因多态性与动脉粥样硬化性脑梗死的相关性研究[J].中国现代药物应用,2020,14(9):31-33.
[33] 宋楠,秦川.PPARγ在阿尔茨海默病中的作用及影响因素研究进展[J].医学研究生学报,2015,28(9):989-994.
[34] QUINTANILLA RA, UTRERAS E, CABEZAS-OPAZO FA. Role of PPAR gamma in the Differentiation and Function of Neurons. PPAR Res. 2014; 2014:768594.
[35] MA RH, ZHANG Y, HONG XY, et al. Role of microtubule-associated protein tau phosphorylation in Alzheimer’s disease. J Huazhong Univ Sci Technolog Med Sci. 2017;37(3):307-312.
[36] WANG JC, ZHU K, ZHANG HY, et al. Early active immunization with Aβ3-10-KLH vaccine reduces tau phosphorylation in the hippocampus and protects cognition of mice. Neural Regen Res. 2020;15(3):519-527.
[37] ESCRIBANO L, SIMÓN AM, GIMENO E, et al. Rosiglitazone rescues memory impairment in Alzheimer’s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology. 2010;35(7):1593-1604.